Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 600 participants.
Also called NCT05225077
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 600 participants
- Sponsor
- Registry
-
NCT05225077
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Unknown status
Technical summary
Registry record NCT05225077. Randomized; no masking; primary purpose prevention. Start 2022-01-01 (actual); primary completion 2022-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients
- Condition
- Renal Insufficiency, Chronic
- Condition
- Cardiac Catheterization
- Condition
- Percutaneous Coronary Intervention
- Intervention (Drug)
- Dapagliflozin 10 MG [Farxiga]
- Lead sponsor
- Dong-A University
Record details
- Record id
cardio:ct-nct05225077- Content hash
c4368d065bd8bfd09f847fbdebb6d0278bd78a7da26611a656e6329a51990852